The absence of positive cash flow generation, coupled with a -41.85% net margin, suggests that the firm is burning through its limited $7.65 million liquidity buffer to sustain operations.
| Metric | Dec'24 | Dec'23 | Dec'22 | Dec'21 |
|---|
| Cash from Operations | -16.13M | -45.8M | -22.02M | -15.68M |
| Operating CF Margin % | -4.71% | -15.02% | -8.98% | -7.28% |
| Operating CF Growth % | 64.78% | -108% | -40.4% | - |
| Net Income | -37.37M | -36.95M | -19.83M | -96.18M |
| Depreciation & Amortization | 134.51K | 112.09K | 0 | 21.32M |
| Stock-Based Compensation | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 3.57M | 3.6M | -774.45K | 24.05M |
| Working Capital Changes | 17.53M | -12.56M | -1.41M | 35.14M |
| Change in Receivables | 16.45M | -4.45M | -26.75M | -917.34K |
| Change in Inventory | 3.03M | -5M | -77.56K | -1.59M |
| Change in Payables | -16.34M | -1.66M | 12.94M | 5.43M |
| Cash from Investing | -33.37K | -111.89K | 0 | -500K |
| Capital Expenditures | -37.77K | -111.89K | 0 | 0 |
| CapEx % of Revenue | 0.01% | 0.04% | - | - |
| Acquisitions | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - |
| Other Investing | 4.4K | 0 | 0 | 0 |
| Cash from Financing | 17.02M | 50.07M | 22.49M | 5.44M |
| Debt Issued (Net) | 17.02M | 52.34M | 22.49M | 5.44M |
| Equity Issued (Net) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 |
| Other Financing | 0 | -2.28M | 0 | 0 |
| Net Change in Cash | 846.6K | 4.16M | 474.66K | -10.74M |
| Free Cash Flow | -16.17M | -45.91M | -22.02M | -15.68M |
| FCF Margin % | -4.72% | -15.06% | -8.98% | -7.28% |
| FCF Growth % | 64.78% | -108.51% | -40.4% | - |
| FCF per Share | -2.46 | -6.98 | -3.35 | -2.38 |
| FCF Conversion (FCF/Net Income) | 0.11x | 0.31x | 0.18x | 0.08x |
| Interest Paid | 2.74M | 2.39M | 3.24M | 4.05M |
| Taxes Paid | 0 | 0 | 0 | 0 |
Imminent liquidity shortfall risk
Given the absence of reported cash flow data, the significant -41.85% net margin suggests that the company's accrual-based earnings are likely disconnected from actual cash generation, warranting extreme caution regarding the firm's ability to convert its reported revenue growth into sustainable operating cash flow.
The wide disparity between top-line expansion and deep net losses implies that the company may be relying on aggressive accounting or high non-cash expenses to sustain its operations. Investors should monitor whether the underlying cash conversion cycle is being strained by the need to fund inventory for its 1P pharmaceutical model.
Based on the reported $7.65 million cash position relative to a $342 million revenue base, the company's cash flow trajectory appears highly precarious, suggesting that the firm is likely burning through its remaining liquidity to support its current operational scale and market acquisition strategy.
The lack of positive free cash flow generation in a high-volume, low-margin environment indicates that the company may be unable to self-fund its growth. This trajectory suggests that external financing is likely required in the near term to prevent a total depletion of working capital.
As indicated by the company's 13.92% gross margin, the reliance on a first-party pharmaceutical inventory model likely creates significant working capital pressure, as the firm must tie up limited cash in stock that faces potential obsolescence and intense price competition in the Chinese market.
The efficiency of the company's cash cycle is likely hampered by the need to maintain high inventory levels to ensure fulfillment for chronic care patients. Any delay in collections or inventory turnover would further exacerbate the already thin liquidity position and increase the risk of operational disruption.
While the provided data lacks a formal cash flow statement, the deep net losses suggest that significant cash is being consumed by non-operating items, potentially including high customer acquisition costs or capitalized expenses that obscure the true, underlying cash burn rate of the business.
The discrepancy between the company's reported revenue growth and its negative net margin warrants further investigation into whether cash is being diverted to support loss-leading services. Analysts should be wary of potential off-balance-sheet liabilities or financing arrangements that may be masking the true severity of the cash shortfall.
Quick answers to the most common questions about buying POM stock.
POMDOCTOR Ltd (POM) generated $-16.1M in net cash from operating activities in 2024. This reflects the cash generated directly from core business operations.
POMDOCTOR Ltd (POM) reported negative free cash flow of $16.2M in 2024, indicating capital requirements exceeded cash from operations.
POMDOCTOR Ltd (POM) spent $0.0M on capital expenditures in 2024. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.